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A B S T R A C T
Background: Beta-endorphin (BE) has been suggested to play a central role as to why people engage in NSSI. To
our knowledge, no study has systematically assessed this potential relationship in adolescents with NSSI.
Methods: 94 adolescents with NSSI (according to DSM-5 criteria) and 35 healthy controls (HC) were enrolled. All
participants received heat pain stimulation, with pain threshold and tolerance measured in °C. Plasma BE levels
were assessed. Sociodemographic and clinical characteristics were obtained via semi-structured interviews and
self-report questionnaires.
Results: Adolescents with NSSI showed increased pain thresholds (t(127)=2.071, p=.040), lower pain intensity
(t(114)==2.122, p=.036) and lower plasma BE levels (t127==3.182, p=.002) compared to HC. Groups did not
differ on pain tolerance (t(127)=0.911, p=.364). Greater pain threshold correlated positively with borderline
personality disorder (BPD) symptoms (r=0.182, p=.039), while pain intensity (r=-0.206, p=.033) and BE
levels (r=-0.246, p=.007) correlated negatively with depression severity. No significant relationship was found
between pain threshold and plasma BE (r=-0.013, p=.882).
Limitations: Future studies should implement repeated plasma BE measures to assess BE release in association
with pain in NSSI. Validity of plasma BE measures compared to central measures should be considered. Assessing
the association between pain sensitivity (PS) and BE in a naturalistic setting presents a promising avenue for
future research in NSSI.
Conclusions: Findings support both reduced PS and basal opioid deficiency as independent biological correlates
and potential risk-factors for NSSI. Further longitudinal and experimental studies are needed to investigate the
role of BE levels and PS as well as their potential association.
1. Introduction
Non-suicidal self-injury (NSSI) is defined as the deliberate and self-
inflicted hurting or destruction of one's own body tissue without sui-
cidal intent (International Society for the Study of Self-injury, 2018;
Nock, 2010). Commonly, NSSI has its onset in adolescence; with life-
time prevalence rates of 17.2% for adolescents (Swannell et al., 2014),
it presents a serious threat to psychosocial development during ado-
lescence. Despite being a key symptom of borderline personality
disorder (BPD), NSSI frequently accompanies other psychiatric dis-
orders, e.g. major depressive disorder (MDD), thereby affecting a het-
erogeneous clinical population (Glenn and Klonsky, 2013; Nock, 2009).
Reasons for engaging in NSSI have been linked to negative affect, dis-
sociation and emotion dysregulation, with NSSI serving as a dysfunc-
tional coping mechanism (Klonsky, 2007). These phenotypes under-
lying NSSI are commonly found in both BPD and MDD. In addition to
diverse types of psychopathology, the experience of adverse childhood
experiences (ACE) has been defined as a central risk factor for the
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occurrence of NSSI (Cipriano et al., 2017; Glenn and Klonsky, 2013),
with up to 80% of individuals with a history of NSSI reporting ACE
(Gratz et al., 2002). However, NSSI also occurs independently
(Zetterqvist, 2015) without comorbid psychiatric disorders
(Wilkinson, 2013), supporting the notion of NSSI as an independent
disorder (American Psychiatric Association, 2013). So far, research has
focused on psychological functions and risk factors related to the oc-
currence of NSSI, yet its underlying biological mechanisms are still
poorly understood.
Based on reports that individuals with a history of NSSI feel little to
no pain (hypo-/analgesia) during or following self-injury (Nock and
Prinstein, 2005), researchers proposed alterations in pain processing as
a potential risk factor for NSSI (Nock, 2010). Pain perception and
processing are complex, comprising sensory, affective and cognitive
dimensions (Navratilova and Porreca, 2014), including the involvement
of a number of brain areas (e.g. anterior cingulate cortex (ACC),
amygdala, insula, prefrontal cortex) that are largely interconnected,
serving somatosensory and affective/cognitive aspects of the holistic
pain sensation (Garland, 2012; Price, 2000). While noxious stimuli are
normally perceived as aversive, resulting in avoidance as a self-pre-
serving measure, Nock hypothesized that individuals with lower pain
sensitivity (PS), and subsequently no aversion to anticipated pain, are at
greater risk to engage in NSSI (Nock, 2010). These assumptions were
confirmed in two research reviews that reported significantly higher
pain threshold and tolerance in individuals with a history of NSSI across
all age groups (Kirtley et al., 2016; Koenig et al., 2016). Further support
stems from recent neuroimaging studies showing that reduced PS seems
to be related to altered pain perception, with altered activation patterns
following painful stimuli in brain areas commonly associated with af-
fective and cognitive processes of pain perception (Schmahl et al.,
2006, 2004). Initial theories hypothesized processes of habituation as
an explanation for lowered PS in individuals with NSSI (Joiner, 2007).
However, with recent studies yielding no support for these assumptions
(Koenig et al., 2017b), a potential role of comorbid psychopathology
has been discussed. Consistently, PS was found to be negatively corre-
lated with the severity of BPD symptomatology (Ludäscher et al., 2009),
as well as with MDD (McCoy et al., 2010; Thompson et al., 2016).
Moreover, emotion dysregulation, self-criticism and neuroticism –
central characteristics in BPD and depression alike
(American Psychiatric Association, 2013; Bradley et al., 2011) – were
found to be associated with lowered PS (Bunderla and
Kumperščak, 2015; Franklin et al., 2012), with emotion dysregulation
accounting for significant variance in the association between NSSI and
pain tolerance (Franklin et al., 2012). Further, ACE have been related to
lower PS (Fillingim and Edwards, 2005) and are central risk factors for
BPD (Lieb et al., 2004), MDD (Bradley et al., 2011), dissociation
(Korzekwa et al., 2009) and emotion dysregulation (Lieb et al., 2004).
These findings support the assumption of a complex relationship be-
tween PS and comorbid psychopathology in NSSI. Nevertheless, more
research is warranted to assess the nature of these associations.
A well-established relationship exists between analgesia, pain per-
ception and the endogenous opioid system, one of the innate pain-re-
lieving systems (Akil et al., 1984). Especially the activity of µ- and δ-
receptors is linked to the reduction of pain perception
(Benarroch, 2012; Bresin and Gordon, 2013), emphasizing foremost the
role of beta-endorphin (BE) as a µ- and δ-receptor agonist. µ- and δ-
receptors, and BE are present in both the central and peripheral nervous
system (Benarroch, 2012; Rachinger-Adam et al., 2011), and modula-
tion of pain perception and analgesia are exerted through central and
peripheral nervous BE release alike (Benarroch, 2012; Stein et al.,
2009). Consistently, Zubieta and colleagues showed that increased µ-
opioid receptor activity in the ACC is linked to lower self-reported le-
vels of pain unpleasantness and that increased µ-opioid receptor ac-
tivity in the amygdala is linked to lower perceived pain intensity
(Zubieta et al., 2001). Further, Bruehl and colleagues showed that
resting plasma BE levels predicted analgesic response to morphine in
chronic pain patients (Bruehl et al., 2017). Based on the existing lit-
erature, the potential role of BE in NSSI has come to increasing atten-
tion. In line with the small number of existing studies, opioid deficiency
theories suggest that people engaging in NSSI have lower resting levels
of BE and, driven by an innate desire to restore a homeostasis, engage in
actions, such as NSSI, that are likely to result in releases of BE
(Bresin and Gordon, 2013; Hooley and Franklin, 2018). First support for
these models was drawn from animal studies illustrating that rhesus
monkeys with a history of self-biting behavior showed lower basal
plasma levels of BE than a matched group of monkeys without such
behavior (Tiefenbacher et al., 2005). Stanley and colleagues reported
lower BE levels in cerebral spinal fluid (CSF) in participants with per-
sonality disorders, a history of suicide attempts and a history of NSSI
(Stanley et al., 2010). Prossin and colleagues, using positron emission
tomography (PET), found lower µ-opioid receptor activity in the orbi-
tofrontal cortex and the left amygdala in individuals with BPD
(Prossin et al., 2010). Despite some empirical support of these theore-
tical models, studies are limited mostly to animal models or assessed
the role of changes in BE in different psychiatric disorders without as-
sessing NSSI (Prossin et al., 2010). Additionally, most human studies
solely included adults.
NSSI is most common in adolescents (Nock, 2010) and marks a
serious risk factor for future suicide attempts, risk-taking behaviours,
and potential long-term mental health problems, even beyond cessation
into adulthood (Brown and Plener, 2017). While some evidence sug-
gests altered biological mechanisms are already present in adolescence
(Kirtley et al., 2016; Koenig et al., 2016), more research in adolescent
populations is needed in order to increase the understanding of this
phenomenon. A focus on younger samples further allows to rule out
effects of long-term illness and secondary effects of chronification, as
well as age-dependent differences in the endogenous opioid systems
(Gibson and Farrell, 2004). Thus, in this study, we aimed to system-
atically investigate PS and basal BE levels in adolescents with NSSI
compared with a group of healthy matched controls. We hypothesized
that adolescents with NSSI show altered PS (indexed by higher pain
threshold and tolerance, and lower pain intensity). In addition, we
hypothesized that adolescents engaging in NSSI show lower resting
plasma BE levels. Given the high comorbidity of NSSI, we further ex-
plored potential associations between PS and BE with BPD symptoms,
depressive symptoms, trauma severity and general psychiatric symptom
severity, respectively. Finally, our study is the first to assess the po-
tential association between altered plasma BE levels and PS in adoles-
cent NSSI.
2. Methods
2.1. Participants
Patients with NSSI were recruited from the outpatient clinic for risk-
taking and self-harm behavior “Ambulanz für Risikoverhalten und
Selbstschädigung (AtR!Sk)” (Kaess et al., 2017) at the Department of
Child and Adolescent Psychiatry, University of Heidelberg. Following
an initial diagnostic assessment, patients are invited to participate in
the nested AtR!Sk-Bio cohort, which is an ongoing study aiming at
identifying biological correlates of risk-taking and self-harming beha-
vior in adolescence. The Ethics Committee of the Faculty of Medicine,
University of Heidelberg, approved the scientific evaluation of AtR!Sk
(IRB approval number S-449/2013) and the add-on neurobiological
assessments (IRB approval number S-514/2015).
Recruitment for AtR!Sk-Bio takes places within six weeks after the
diagnostic assessment in AtR!Sk. Inclusion criteria comprise: age 12–17
years; completed diagnostic assessment; informed and written consent
of adolescents and their caregivers. Patients showing acute psychotic
symptoms or lacking speech comprehension are excluded. For the
present analyses, only patients fulfilling the criteria for NSSI, defined as
five or more incidents of NSSI in the last 12 months according to the
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DSM-5 (American Psychiatric Association, 2013), were included. Fur-
ther, based on known sex-differences regarding the prevalence of NSSI
and PS, only data from female patients were considered. Healthy con-
trols (HC) were recruited via public advertisements and underwent an
adapted form of the diagnostic assessment used in AtR!Sk. Eligibility
criteria for HC comprised: age 12–17 years; no history of NSSI; no en-
dorsement of any psychiatric disorder and no treatment for any psy-
chiatric disorder prior to participation in the study. All HC and their
caregivers provided informed and written consent to participate in the
study. Due to the ongoing nature of the AtR!Sk and AtR!Sk-Bio studies,
August 2018 was chosen as cut-off for inclusion in the present study. All
participants (patients with NSSI and HC) that had completed the neu-
robiological assessment until August 2018 were subsequently con-
sidered for analyses.
2.2. General procedures
The study comprised two separate appointments. The first ap-
pointment consisted of the diagnostic assessment for the patient group
and the HC respectively, with relevant instruments described below
(see 2.3.). The biological assessment, marking the second appointment,
started at 8 a.m. with measures of height and weight, as well as ques-
tions regarding participants’ smoking habits; physical illness within the
past three months; and regular medication intake. To account for po-
tential interferences with the blood draw, participants were asked
whether they were fasting as instructed, as well as to their cigarette
consumption at the day of the assessment. Next, the fasting blood draw
described in detail below (see 2.4.) followed. After a resting period, PS
was assessed as described below (see 2.5.). All participants received 40€
upon completion of the neurobiological assessment.
2.3. Measures
NSSI and suicide attempts were measured using single items of the
German version of the Self-Injurious Thoughts and Behaviors Interview
(SITBI-G) (Fischer et al., 2014), a semi-structured interview for the
detailed assessment of self-injurious thoughts and behaviours that was
slightly modified to meet DSM-5 criteria for NSSI. The SITBI-G was
carried out in its entirety and shows good psychometric properties
(Fischer et al., 2014). BPD symptoms were assessed using the respective
part of the German version of the Structured Clinical Interview for DSM-IV
Axis II Personality Disorders (SCID-II) (Wittchen et al., 1997), with items
showing good internal consistency (Cronbach's α = 0.83). In addition,
patients underwent the Mini International Neuropsychiatric Interview for
Children and Adolescents (MINI-KID) (Sheehan et al., 2004), a short
semi-structured interview designed to assess common axis I psychiatric
disorders in children and adolescents aged 6–19 years. Self-reported
depressive symptoms were measured using the Depression Inventory for
Children and Adolescents (DIKJ) (Stiensmeier-Pelster et al., 2000). The
26 items of the DIKJ were constructed based on DSM-IV criteria for
depression, showing excellent psychometric properties (Stiensmeier-
Pelster et al., 2000). Similarly, we found excellent internal consistency
in the present study (Cronbach's α = 0.95). Severity of psychiatric
symptoms was rated based on the Clinical Global Impressions-Severity
(CGI-S) (Busner and Targum, 2007) scale; This seven-point scale re-
quires the clinician to rate how mentally ill a patient is, based upon
observed and reported symptoms, behavior and function over the past
seven days. To account for ACE, all participants completed the German
translation of the Childhood Experiences of Care and Abuse questionnaire
(CECA.Q) (Kaess et al., 2011), showing good psychometric properties.
The CECA.Q items were taken directly from the interview version and
adapted, covering modules for parental care (antipathy and neglect),
physical abuse and sexual abuse. To assess trauma severity, we created
a dimensional trauma score using four modules of the CECA.Q, showing
moderate to excellent internal consistency (Cronbach's α: antipathy
(maternal α = 0.91; paternal α = 0.92), neglect (maternal α = 0.83;
paternal α = 0.92), physical abuse (maternal α = 0.60; paternal
α = 0.70), sexual abuse (α = 0.85)). Following dichotomization of each
variable, a mean score ranging from 0 (no trauma) to 1 (multiple
trauma) was generated for each participant. Smoking behavior and
tobacco use were assessed during the first appointment using a short
questionnaire, as well as during the second appointment using
screening questions to account for potential influences on BE. While
inconclusive, current literature indicates that acute nicotine adminis-
tration could increase BE levels, while chronic exposure could even-
tually inhibit the biosynthesis of beta-endorphin, leading to a chronic
decrease in beta-endorphin levels (del Arbol et al., 2000; Tziomalos and
Charsoulis, 2004).
2.4. Blood draws
Fasting blood samples were collected between 8:30 a.m. and 9:00
a.m. by trained medical personal via venepuncture from the crook of
the arm, under sterile conditions. Blood samples were subsequently sent
to the central laboratories of the Heidelberg University Hospital for
further analyses. BE levels were determined using an enzyme-linked
immunosorbent assay (ELISA) by Cloud Clone (Houston, TX, US), ac-
cording to the protocol of the manufacturer. Blood samples were left to
rest at room temperature for two hours, before being centrifuged for
20 min at 1000xg and stored at -18 °C within the central laboratories
until assay. To determine BE levels, samples were thawed to room
temperature and 50µL were added to each well of pre-coated 96-well
strip plates. 50µL/well of detection reagent A were added and the plates
were set to incubate for 1 hour at 37 °C. After incubation, the wells were
washed and 100µL of detection reagent B were added to each well.
Following incubation for 30 min at 37 °C, the wells were washed again
and 90µL of substrate solution was added. The wells were incubated,
protected from light, for 10 – 20 min at 37 °C. Subsequently, 50µL of
Stop solution were added to each well. After the liquids mixed uni-
formly, absorbance was measured immediately at 450 nm. Samples
were tested in duplicate. Central and peripheral BE play a role in the
modulation of pain perception and analgesia (Benarroch, 2012;
Stein et al., 2009), however plasma BE levels have been found to be
sensitive to effects of stress (De Riu et al., 1997). Despite this sensitivity,
studies assessing resting plasma BE levels across repeated sessions were
able to show that resting plasma BE levels remained relatively stable
(Bruehl et al., 2017; Leppäluoto et al., 2008), supporting the assump-
tion that resting plasma BE levels are a reliable and relatively stable
marker.
2.5. Pain sensitivity
PS was assessed using an AHP-1800CPV Versatile Cold/Hot Plate
(TECA Corp., Chicago, IL, USA) and a predefined programmed sequence
for the temperature. Baseline adaptation temperature was set at 32 °C.
Temperature was sealed off at 50 °C to avoid tissue damage.
Participants were instructed to place their non-dominant hand flat on
the plate as soon as baseline temperature was reached. After a 3-minute
adaptation phase, temperature raised up to 50 °C within 4 min, in-
creasing linear by 1 °C over 13.3 s. Participants were asked to keep their
hand firmly on the plate until the pain became intolerable. Temperature
at the first pain sensation (pain threshold) and temperature at intoler-
able pain sensation (pain tolerance) was measured in °C. Pain intensity
was assessed via visual analogue scale (VAS) using the Continuous
Measurement System (CMS) software (Messinger et al., 2009). When
pain threshold was reached, participants were instructed to con-
tinuously rate pain intensity on a scale from 0 to 100 using their
dominant hand until pain tolerance was reached. If pain tolerance was
not reached at 50 °C, the sequence ended automatically and partici-
pants were asked to remove their hand. For the present study, pain
intensity scores were calculated for each participant based on the rated
pain intensity upon reaching pain tolerance. To account for potential
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inaccuracies, an average score was generated, using all VAS ratings
within five seconds prior to- and following attained pain tolerance.
2.6. Statistical analysis
Prior to analyses, the main variables (NSSI, BE, pain threshold, and
tolerance) were checked for missing values. BE data were additionally
checked and corrected using sensitivity analyses. Sociodemographic
and clinical variables were tested for between-group differences using
two-sided t-tests and χ²-tests respectively. Between-group differences
regarding pain threshold and tolerance, as well as between-group dif-
ferences regarding pain intensity and plasma BE levels were analysed
using two-sided t-tests. To account for the potential influence of
smoking behavior on BE, we calculated a regression model with BE as
dependent variable and group, smoking prior to the neurobiological
assessment and smoking during the last 12 months as independent
variables. In additional regression models the potential influence of
medication intake and body-mass-index (BMI) on BE and PS was as-
sessed. Next, Pearson product-moment correlations were used to assess
associations between pain threshold, intensity and tolerance, and BE.
Finally, we conducted exploratory analyses, using Pearson product-
moment correlations, to assess potential associations between clinical
characteristics and pain threshold, intensity, tolerance, and BE respec-
tively. Analyses regarding the number of NSSI episodes and severity of
psychiatric symptoms were solely conducted for the patient group. All
analyses were performed using Stata (Version 16; StataCorp LP, College
Station, TX, USA) with the significance level set to α = 0.05.
Adjustments for simultaneously testing two directed hypotheses were
not performed, as tests were two-sided. No a priori power analysis was
conducted, as the studies, from which the data stem, are still ongoing
and do not aim at recruiting up to an a priori fixed number of partici-
pants.
3. Results
3.1. Sample characteristics
For the present analyses, only data from participants up to August
2018 were included. Since recruitment for the AtR!Sk-Bio cohort
started in August 2016, n = 203 patients passed the diagnostic as-
sessment in AtR!Sk, making them eligible for the additional neurobio-
logical assessments of AtR!Sk-Bio. N= 148 patients had completed the
neurobiological assessments until August 2018 (participation rate:
72.9%). Of these, n = 31 (20.9%) patients were excluded due to not
meeting DSM-5 criteria for NSSI. N= 10 patients (6.8%) were excluded
due to male sex. Of the remaining n = 107 patients, n = 17 (11.5%)
were excluded due to missing BE (n= 16; 10.8%) or pain data (n= 1;
0.7%). Data from one patient was excluded because this patient had,
with 224.1 µg/ml, an extremely high BE value (the next highest value
was 97.7 µg/ml). Sensitivity analyses showed that this patient had an
undue influence on results. N = 40 healthy female adolescents were
recruited as control group, with n = 5 (12.5%) being excluded from
analyses for missing BE data due to an insufficient quantity of blood for
assay. The final study sample consisted of n = 94 female patients with
NSSI and n = 35 HC.
Sociodemographic and clinical characteristics of the study sample
are presented in Table 1. No significant difference could be found re-
garding mean age, height, weight, or body-mass-index (BMI). Partici-
pants differed significantly regarding school type, (χ²(3)=16.07,
p=.001). N= 20 (15.5%) participants were taking at least one form of
medication (NSSI: n = 19, 14.7%; HC n = 1, 0.8%). Patients were
significantly more likely to have smoked in the past 12 months com-
pared to HC (χ²(6)=16.62, p=.011). Similarly, significantly more pa-
tients had smoked prior to the neurobiological assessment compared to
HC (χ²(1)=4.48, p=.034).
Patients reported on average 70.66 (SD=70.01) episodes of NSSI
within the past 12 months. Mean age of onset for NSSI was 12.85 years
(SD=1.36) and on average, patients reported engagement in NSSI for
1.9 years (SD=1.66). N = 42 patients (44.7%) reported at least one
previous suicide attempt, with an average of 3.41 (SD=6.42) lifetime
attempts. N = 89 patients fulfilled diagnostic criteria for at least one
psychiatric disorder (MINI-KID). On average, patients endorsed 3.37
(SD=0.22) BPD criteria, with n = 30 (31.9%) patients fulfilling the
diagnostic threshold for BPD diagnosis. Further, n = 52 (58.4%) pa-
tients fulfilled the diagnostic threshold for either a depressive episode
(n = 35) or recurrent depressive disorder (n = 17). Patients scored
significantly higher on depressive symptoms (DIKJ) compared to HC (t
(116)=14.993, p<.001). Patients reported significantly higher ACE
compared to HC (χ²(1)=32.38, p<.001).
3.2. Pain ratings
The NSSI group showed a significantly higher pain threshold com-
pared to HC (NSSI: M=43.27, SD=3.77, HC: M=41.77, SD=3.36; t
(127)=2.071, p=.040, 95% CI[-0.80, -0.02], Cohen's d=0.41; Fig. 1).
No significant differences between groups were found on measures of
pain tolerance (NSSI: M=47.16, SD=2.47, HC: M=46.73, SD=2.17; t
(127)=0.911, p=.364, 95% CI[-0.57, -0.021], Cohen's d=0.18; Fig. 1).
The NSSI group reported a significantly lower pain intensity compared
to HC (t(114)=-2.122, p=.036, 95% CI[0.03, 0.84], Cohen's d=0.44).
For exploratory analyses, we further assessed potential associations
between clinical characteristics and PS (pain threshold, pain tolerance,
and pain sensitivity respectively). Pain threshold showed a significant
positive correlation with BPD symptoms (r=0.182, p=.039; Fig. 2). No
significant relationship was found between pain threshold and the
number of NSSI episodes in the past 12 months (r=-0.064, p=.543),
depression scores (DIKJ; r=0.091, p=.325), severity of psychiatric
symptoms (CGI; r=-0.037, p=.729) or severity of ACE (r=0.101,
p=.270). No significant relationship was found between pain tolerance
and BPD symptoms (r=0.104, p=.239), number of NSSI episodes in the
past 12 months (r=-0.098, p=.347), depression scores (DIKJ; r=0.003,
p=.976), severity of psychiatric symptoms (CGI; r=-0.032, p=.763) or
severity of ACE (r=0.037, p=.687). Pain intensity showed a significant
negative correlation with depression scores (r=-0.206, p=.033). No
significant relationship was found between pain intensity and BPD
symptoms (r=-0.108, p=.250), number of NSSI episodes in the past 12
months (r=0.080, p=.474), severity of psychiatric symptoms (CGI;
r=0.037, p=.743) or severity of ACE (r=0.049, p=.607). Additional
exploratory analyses were conducted to determine what factors explain
unique variance in PS. Sub-group analyses within the NSSI group re-
vealed no significant differences for patients with BPD compared to
patients without BPD (pain threshold: t(92)=-0.549, p=.585; pain
tolerance: t(92)=0.437, p=.663; pain intensity: t(81)=-0.642,
p=.523), patients with MDD compared to patients without MDD (pain
threshold: t(92)=1.042, p=.300; pain tolerance: t(92)=-0.235,
p=.815; pain intensity: t(81)=1.214, p=.228) and patients with pre-
vious suicide attempts compared to patients without previous suicide
attempts (pain threshold: t(92)=-0.391, p=.696; pain tolerance: t(92)
=-0.595, p=.553; pain intensity: t(81)=-0.497, p=.621). Subse-
quently, multiple regressions, using group, BPD symptoms and de-
pression scores as independent variables, revealed a significant multiple
regression model for pain threshold (F(3, 114)=3.68, p=.014), with an
adjusted R2 of 0.06. However, no significant predictors could be found:
group (β=0.29, p=.074), BPD symptoms (β=0.23, p=.053), depres-
sion scores (β=-0.29, p=.070). Finally, stepwise regressions were
performed to assess best model fit for individual factors. BPD symptoms
significantly predicted pain threshold, b=0.39, t(118)=2.65, p=.009,
with the model explaining a significant proportion of variance in pain
threshold, R²=0.06, F(1, 116)=7.02, p=.009. Group significantly pre-
dicted pain intensity, b=-9.66, t(118)=-2.20, p=.030, with the model
explaining a significant proportion of variance in pain threshold,
R²=0.04, F(1105)=4.85, p=.030.
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3.3. Beta-Endorphin
The groups differed significantly on plasma BE levels (t(127)
=-3.182, p=.002, 95% CI[0.23, 1.03], Cohen's d=0.63): As depicted in
Fig. 3, patients had significantly lower BE levels (M=26.21 pg/ml,
SD=20.64) compared to the HC (M=39.02 pg/ml, SD=19.45). Re-
garding a potential influence of smoking habits, a significant regression
equation was found for the multiple regression model (F(3, 125)=4.25,
p=.007), with an R2 of 0.093. Group significantly predicted BE levels
(β=-12.55, p=.004), while smoking prior to the neurobiological as-
sessment (β=-11.57, p=.110) and smoking over the last 12 months
(β=3.53, p=.460) had no significant influence.
Further, in several exploratory analyses, we assessed potential as-
sociations between clinical characteristics and plasma BE levels. A
significant negative correlation was found between BE levels and de-
pression scores (DIKJ: r=-0.246, p=.007, Fig. 4). No significant re-
lationship was found between BE levels and the number of NSSI epi-
sodes in the past 12 months (r=0.086, p=.412), BPD symptoms (r=-
0.100, p=.258), severity of psychiatric symptoms (CGI: r=0.052,
Table 1
Sociodemographic characteristics of the study sample.
Variable Group; mean± SD or N (%) Effect Sizeb Pa
HC, (n = 35) NSSI, (n = 94)
Age (yr) 14.9 ± 1.29 14.9 ± 1.44 0.03 0.877
Height (cm) 164.5 ± 5.39 165.9 ± 6.26 0.25 0.211
Weight (kg) 57.6 ± 10.91 61.7 ± 14.06 0.31 0.116
BMI 21.2 ± 3.29 22.37± 4.79 0.27 0.183
School Typec 0.35 <0.001
Gymnasium 26 (74.3) 35 (37.2)
Realschule 8 (22.9) 34 (36.2)
Hauptschule 0 (0.0) 11 (11.7)
Other 1 (2.8) 14 (14.9)
Smoked past 12 months 9 (25.7) 50 (53.2) 0.36 0.011
Smoked prior bio. Assess. 0 (0) 11 (11.7) 0.19 0.034
ICD-10 Diagnoses
Organic, including symptomatic, mental disorders – 0 (0) –
Mental and behavioural disorders due to psychoactive substance use – 20 (21.3) –
Schizophrenia, schizotypal and delusional disorders – 0 (0) –
Mood [affective] disorders – 60 (63.8) –
Neurotic, stress-related and somatoform disorders – 42 (44.7) –
Behavioural syndromes associated with physiological disturbances and physical factors – 12 (12.8) –
Disorders of adult personality and behavior – 35 (37.2) –
Mental retardation – 0 (0) –
Disorders of psychological development – 1 (1.1) –
Behavioural and emotional disorders with onset usually occurring in childhood and adolescence/Unspecified mental
disorder
– 21 (22.3) –
DIKJd 5.4 ± 3.62 29.6 ± 9.12 3.05 <0.001
CGId - 5.04± 0.69
CECA.Qd
Experienced ACE 3 (8.6) 57 (65.5) 0.52 <0.001
BMI = body mass index; DIKJ = Depressionsinventar für Kinder und Jugendliche; CGI = clinical global impression; CECA.Q= Childhood Experiences of Care and Abuse
questionnaire.
a Significance: Values refer to differences between groups, with t-tests for continuous variables and χ2 tests for categorical variables.
b Effect Size; Effect sizes were calculated using Cohen's d for t-tests and Cramer's V for χ
2
tests.
c Hauptschule: secondary school terminating with a lower secondary-school level II certificate: Realschule: secondary school terminating with a secondary-school
level I certificate; Gymnasium: secondary school terminating with the general qualification for university entry.
d Due to missing data, analyses were carried out with varying N for HC and NSSI-group: DIKJ (N= 34 HC & N= 84 NSSI); CGI (N= 92 NSSI); CECA.Q (N= 35
HC & N = 87 NSSI).
Fig. 1. Group differences in pain ratings. NSSI = Non-suicidal self-injury.
Fig. 2. Correlation scores between BPD symptoms and pain threshold.
BPD = Borderline personality disorder.
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p=.621) or severity of ACE (r=-0.126, p=.168). Similarly, no sig-
nificant relationship was found between BE levels and pain threshold
(r=-0.013, p=.882), pain tolerance (r=0.053, p=.553) and pain in-
tensity (r=0.012, p=.898). Again, additional exploratory analyses
were conducted to determine what factors explain unique variance in
BE levels. Sub-group analyses within the NSSI group revealed no sig-
nificant differences for patients with BPD compared to patients without
BPD (t(92)=-0.517, p=.607), patients with MDD compared to patients
without MDD (t(92)=-0.411, p=.682) and patients with previous sui-
cide attempts compared to patients without previous suicide attempts (t
(92)=-0.507, p=.613). Subsequently, using group, BPD symptoms and
depression scores as independent variables, we found a significant
multiple regression model for BE levels (F(3, 114)=4.76, p=.004), with
an adjusted R2 of 0.09. Group significantly predicted BE levels (β=-
0.40, p=.014), while BPD symptoms (β=0.15, p=.211) and depression
scores (β=0.15, p=.915) had no significant influence. Finally, a step-
wise regression was performed to assess best model fit for individual
factors. Group significantly predicted BE levels, b=-13.84, t(118)
=-3.56, p<.001, with the model explaining a significant proportion of
variance in BE levels, R²=0.10, F(1, 116)=12.70, p<.001.
4. Discussion
Adolescents with NSSI had significantly higher pain thresholds and
reported lower pain intensities compared to HC, indicating lower
overall PS. This finding is in line with previous research in adolescents
(Koenig et al., 2017b) and findings on self-harm across all ages
(Koenig et al., 2016). In accordance with more recent findings
(Glenn et al., 2014; Koenig et al., 2017a), we found no association
between a lower PS and NSSI frequency, yielding further support
against previous theories on the effect of habituation (Joiner, 2007). In
line with our second hypothesis, individuals with NSSI had significantly
lower basal BE levels compared to HC. The endogenous opioid system is
a key factor in the experience and processing of pain (Bresin and
Gordon, 2013; Bruehl et al., 2012). In particular, BE release is linked to
a reduction in pain unpleasantness and perceived PS (Zubieta et al.,
2001). Previous research found that adults with a history of NSSI had
altered basal BE levels (Sher and Stanley, 2008). Based on these find-
ings a homeostasis model of NSSI was suggested (Stanley et al., 2010) –
the opioid deficiency model. In line with this model, we demonstrate
robust alterations of basal BE levels in adolescents with NSSI. However,
we found no direct link between plasma BE levels and PS. Important to
note, the opioid deficiency model postulated that BE release, rather
than the baseline BE level, modulates pain experience, with lower
baseline BE levels potentially increasing the sensitivity for the analgesic
effects of BE release (Bresin and Gordon, 2013), subsequently leading to
a lower PS following NSSI. This assumption is supported by studies
showing that increases in µ-opioid receptor availability lead to a
heightened sensitivity for µ-opioid receptor agonists (Bresin and
Gordon, 2013), with other studies showing that BE levels were elevated
following intense physical sensations (Ribeiro et al., 2005;
Sandman and Hetrick, 1995). Further, some evidence exists that BE
levels are elevated following NSSI compared to baseline levels
(Sandman et al., 2003; Sandman and Hetrick, 1995), but these studies
did not assess related pain experience. Unfortunately, we did not assess
BE release in this study. Therefore, while we provide evidence on the
first assumptions of the opioid deficiency model in adolescent NSSI
(lower basal BE level), we were not able to test for effects of BE release.
Overall, the exact role of plasma BE for PS in adolescent NSSI has not
yet been extensively researched. More studies combining assessment of
basal BE and BE release in response to painful stimulation are war-
ranted.
In additional exploratory analyses we assessed potential links be-
tween common comorbid psychopathologies in NSSI, and PS and
plasma BE levels respectively. We found PS to be positively associated
with BPD severity, further supporting assumptions that psycho-
pathology underlying NSSI has a greater effect on PS compared to the
behavior itself. Central functions of NSSI have repeatedly been asso-
ciated with emotion regulation as well as ending dissociative states
(Klonsky, 2007), with the latter seemingly representing a more specific
function of NSSI in the context of BPD (Bracken-Minor and McDevitt-
Murphy, 2014). Stress-related dissociative states as part of the diag-
nostic entity have been reported in up to 80% of individuals with BPD
(Krause-Utz et al., 2017) and were found to be linked to lower PS
(Ludäscher et al., 2010). More precisely, lower PS has been shown to be
related to both state and trait dissociation (Ludäscher et al., 2007;
Russ et al., 1992), with more pronounced effects during times of dis-
tress (Bohus et al., 2000; Stiglmayr et al., 2008). While these findings
could explain our finding of a significant association between PS and
BPD severity, we did not assess measures of dissociation in our study.
Thus, we are unable to verify this assumption.
Further support for the effect of psychopathology underlying NSSI
on PS derives from the significant association between PS and depres-
sion scores. Our finding partly supports current literature of altered
pain processing in depression (McCoy et al., 2010; Thompson et al.,
2016). However, relatively strong heterogeneity has been noted, with
our findings being in line with experimental study designs using ex-
teroceptive painful stimuli (Thompson et al., 2016). The association
could be explained by referring to models of attentional pain proces-
sing, which state that pain might be perceived to a lesser extent if an
individuals’ attention is turned towards other stimuli (e.g. internal
Fig. 3. Group differences in plasma beta-endorphin levels. NSSI = Non-suicidal
self-injury; pg/ml = picogram per milliliter.
Fig. 4. Relationship between plasma beta-endorphin levels and depression
scores.
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thoughts/emotions) (Eccleston and Crombez, 1999). Mood disorders
are characterized by depressed moods, anhedonia and emotion dysre-
gulation (American Psychiatric Association, 2013; Bradley et al., 2011).
As such it seems plausible that, while engaging in NSSI subsequently
helps to regulate emotions and resolve negative affect (Klonsky, 2007),
the initial focus on depressed moods could decrease the subjectively
perceived pain intensity. However, this assumption and the overall
association between PS and depression warrant further research.
An alternative explanation for altered PS could be related to ACE,
either through a direct association between ACE and altered PS or
through an indirect pathway via the role of ACE in the BPD specific
pathology. ACE are a central risk factor for the occurrence of NSSI
(Cipriano et al., 2017; Glenn and Klonsky, 2013) and BPD alike
(Battle et al., 2004; Lieb et al., 2004) with high prevalence rates in both
pathologies (Gratz et al., 2002; Lieb et al., 2004). Regarding the as-
sumption of a direct association between ACE and PS, previous studies
using experimentally induced pain showed that experiencing traumatic
events during childhood was related to an overall lower PS
(Fillingim and Edwards, 2005; Russ et al., 1993). In line with these
findings, we found significantly higher ACE in our NSSI patients com-
pared to our HC. However, we found no direct association between ACE
and altered PS, thus again supporting the potential role of BPD specific
pathology. Apart from its central role in the etiology of BPD, previous
studies further reported ACE as an important risk factor for the occur-
rence of emotion dysregulation and dissociation (Korzekwa et al., 2009;
Lieb et al., 2004). Studies also indicate that the severity of ACE is as-
sociated with the severity of BPD symptoms (Hébert et al., 2018;
Silk et al., 1995; Zanarini et al., 2002). As such, it could be assumed
that higher scores in ACE in our patient group are indicative of in-
creased BPD severity. This could subsequently indicate more severe
emotion dysregulation and more frequent and severe dissociative states,
which modulate the PS (Bekrater-Bodmann et al., 2015).
BE release has previously been associated with analgesic effects,
modulation of reward, emotion regulation, mood-enhancing and an-
xiolytic effects (Bresin and Gordon, 2013; Hegadoren et al., 2009). In
line with these findings, Bandelow and colleagues proposed an intri-
guing theoretical model in which they discuss a potential role of al-
terations in BE in the pathophysiology of BPD (Bandelow et al., 2010).
They propose that the frequently observed risk and attention-seeking
behaviors could be explained by efforts to trigger the rewarding effects
of human attachment, and that NSSI and sensation seeking behaviors
might be direct attempts to artificially increase BE levels. Further, they
assume that the regularly reported feelings of emptiness and anhedonia
might be a result of the reduced availability of BE (Bandelow et al.,
2010). Support for this model comes from experimental studies that
reported lower BE levels in the CSF in individuals with a Cluster B
personality disorder diagnosis with a history of NSSI and at least one
suicide attempt (Stanley et al., 2010), as well as higher BE specific re-
ceptor availability in a number of brain regions in individuals with BPD
(Prossin et al., 2010). However, we found no significant association
between BE levels and BPD severity. As already mentioned by Ban-
delow and colleagues, “it may be argued that it is too simple to attribute
so many behavioral dimensions to just one neurobiological system.”
(Bandelow et al., 2010)(p.631). Thus, assessing BE alone in the context of
BPD might not be enough to elicit significant associations.
Interestingly, we found a significant negative correlation between
BE and depression scores, indicating a link between lower basal BE
levels and greater depression severity. Studies suggested BE as a key
factor for the development and chronification of MDD, due to its role in
emotion regulation (Daley, 2008; Hegadoren et al., 2009). Similar as for
BPD (Bandelow et al., 2010), reduced BE availability has been linked to
the occurrence of anhedonia (Der-Avakian and Markou, 2012) which
could explain our association of greater depression severity with lower
basal BE levels. Further, the association between BE and depression
scores may be linked to our previously reported association between
depression scores and PS. As such, we could assume that lower basal BE
levels lead to more severe depression symptoms, prompting individuals
to engage in NSSI. The increased depression severity could result in a
stronger attentional focus on the internal emotions and states, resulting
in a decreased PS while these individuals engage in NSSI (Bradley et al.,
2011). Based on our present findings, one may speculate on a joint
mechanism, linking affective symptomatology and basal BE in adoles-
cent NSSI. While the mechanisms responsible for alterations in BE are
still largely unknown, the experience of severe and continuous trau-
matic events has previously been associated with decreased levels of BE
(Bremner and Pearce, 2016). However, we found no significant asso-
ciation between ACE and BE. This could be due to the fact that we
assessed ACE as global score. As such, we did not account for severity or
duration of experienced ACE. Future studies including more detailed
assessments of ACE might be able to show an association with BE.
Overall, multiple regression analyses, stepwise regression analyses
and sub-group analyses in the patient sample confirmed that group
status explained most variance in measures of pain intensity and BE.
However, BPD severity was the strongest predictor for pain threshold as
further reflected by the reported correlation. While our exploratory
analyses hint at potential associations between psychopathology, PS
and BE levels respectively, further evidence is needed. As such, future
research is needed to further investigate these associations in well-
powered studies, using a confirmatory approach.
Finally, while the present paper mainly focusses on biological me-
chanisms of NSSI, it is important to consider psychological factors and
their impact on pain perception and BE. Individuals engaging in NSSI
often report an improvement in mood (e.g. decreased negative affect
and increased positive affect) following self-injury, which subsequently
could reinforce future NSSI (Nock and Prinstein, 2004). This phenom-
enon has been suggested to relate to brain circuits involved in emotion
and pain processing (Navratilova and Porreca, 2014). Further, there is
an extensive overlap between neural circuits that process physical pain
and emotional pain (e.g. negative affect and emotional distress), with
evidence indicating that the offset of physical pain results in an offset of
emotional pain (Eisenberger, 2012). In line with this, several studies
were able to show that the offset of pain was indeed associated with a
subsequent reduction in negative affect (Franklin et al., 2010) and an
increase in positive affect (Franklin et al., 2013b, 2013a). As such, it
can be assumed that individuals engaging in NSSI learn to associate an
improvement of mood with NSSI and more precisely the offset of ex-
perienced pain, subsequently reinforcing NSSI due to its rewarding ef-
fects. This is supported by findings where pain relief correlated with the
blood oxygen level-dependent response in brain areas commonly in-
volved in processing pain and reward (Osuch et al., 2014). Further,
studies also showed that the expectation of pain relief leads to altera-
tions in µ-opioid receptor activity in brain regions again associated with
emotion, pain and reward processing (Bushnell et al., 2013;
Wager et al., 2007), potentially indicating that anticipated pain relief
could potentiate pain-related BE release or elicit BE release itself
(Wager et al., 2007). In line with the opioid deficiency model of NSSI
and evidence for increased µ-opioid receptor sensitivity for BE release
(Bresin and Gordon, 2013), it could be assumed that BE release fol-
lowing NSSI also has increased effects on reward circuitry. As such, it
could be assumed that the anticipation of reward (e.g. improvement in
mood) potentiates analgesic effects often observed in individuals with
NSSI, subsequently reinforcing NSSI as behavior.
Further support for a potential impact of psychological factors stems
from findings that individuals with a history of NSSI and high levels of
self-criticism endured pain significantly longer and reported improve-
ment of mood during the experience of pain, which was not found in
individuals with low self-criticism (Fox et al., 2017). This led re-
searchers to assume that mood is improved, because highly self-critical
individuals believe they deserve to be punished and subsequently view
NSSI and pain as self-affirming, thus they are willingly enduring pain
for longer (Hooley and Fox, 2019). In line with the above-mentioned
mechanisms, it can be assumed that high levels of self-criticism are
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distressing, creating emotional pain. The experience of physical pain
might elicit BE release, which subsequently improves mood and re-
inforces NSSI through the effect of BE on reward circuitry. This as-
sumption is further supported by a study that used a brief cognitive
intervention to enhance self-worth in order to reduce self-critical be-
liefs, in individuals with NSSI (Hooley and St. Germain, 2014). Results
showed that an increase in self-worth significantly reduced pain en-
durance, as well as willingness to endure pain in individuals with NSSI
(Hooley and St. Germain, 2014). Again, in line with the above-men-
tioned mechanisms, increasing self-worth with a brief cognitive inter-
vention could be an alternate pathway to reduce the emotional distress,
induced by self-critical beliefs, which reduces the beneficial effect of
pain on mood and subsequently reduces willingness to endure pain.
Following this line of thought, it could be assumed that increasing self-
worth, by reducing self-critical beliefs, is rewarding, potentially in-
dicating a subsequent release of BE. As such, BE levels could already be
increased, reducing the necessity to engage in NSSI to achieve the same
effect. It seems evident that psychological factors impact biological
mechanisms of NSSI (and vice versa), however these interactions are
complex and often hypothetical, as more research is needed.
Our study is not without limitations. First, BE levels were solely
assessed at rest. While findings in two studies indicate that resting BE
levels are a relatively stable measure (Bruehl et al., 2017; Leppäluoto
et al., 2008), future studies should implement multiple measures,
especially before and after the pain stimulation, to enable a more pre-
cise investigation of the adaptive plasma BE response to painful stimuli
and its potential link to PS. Besides, BE measures were assessed from
plasma. Studies have shown that plasma levels of BE are not correlated
with central measures from CSF (De Riu et al., 1997; Kirtley et al.,
2015). Yet, the exact role of plasma BE levels in pain processing re-
mains unknown, and it has been argued that plasma BE levels, which
are easily affected by stress factors (De Riu et al., 1997), could prove
especially useful for studies interested in dynamic measures of BE re-
lease following painful stimuli (Kirtley et al., 2015). It is evident that
further research is necessary to clarify the exact role of BE levels,
central and peripheral alike, in NSSI. While our pain stimulation
paradigm enabled us to systematically assess pain threshold and tol-
erance in an experimental setting, the paradigm itself is very different
from self-inflicted pain associated with actual NSSI. Future studies
should consider using pain stimuli more akin to methods used by in-
dividuals engaging in NSSI (Shabes et al., 2016). It might be worthwhile
to investigate the use of blunted blade stimuli (Ammerman et al., 2018)
as they elicit similar affective and sensory evaluations of pain compared
to real incisions (Shabes et al., 2016). Further, the cross-sectional
nature of the data marks an important limitation. Annual follow-up
measurements could prove valuable to assess temporal changes, to in-
vestigate potential interconnections with other physiological- and
psychological variables and the respective predictive value of altered PS
and lowered BE levels for events of NSSI. Finally, although subjects
were instructed to fast on the morning of testing, we cannot rule out the
possibility that subjects took analgesics before participating in the la-
boratory session.
The large sample of well-characterized adolescents engaging in NSSI
marks a clear strength of the present study. Furthermore, the present
study is, to our knowledge, the first to systematically assess BE and PS
in an adolescent sample.
4.1. Conclusion
The present study found significantly lowered PS (i.e.: increased
pain threshold, lower reported pain intensity) and lower basal BE levels
in adolescents with NSSI, that, in line with previous findings of al-
terations of the endogenous stress system (Koenig et al., 2017b), sug-
gest that significantly altered biological processes are linked to the
onset and maintenance of NSSI. No significant relationship could be
found between increased pain thresholds and lower basal BE levels,
potentially indicating that reduced PS and basal opioid deficiency
might be independent biological correlates for NSSI. There is additional
support of a modulating role of psychopathologies underlying NSSI for
PS and basal opioid deficiency, respectively.
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